미세 버블을 함유하는 피부 외용제 조성물
    31.
    发明公开
    미세 버블을 함유하는 피부 외용제 조성물 审中-实审
    用于外部应用的组合物,包括细小气泡

    公开(公告)号:KR1020120056225A

    公开(公告)日:2012-06-01

    申请号:KR1020110123572

    申请日:2011-11-24

    Abstract: PURPOSE: An external use skin composition containing micro bubbles of O_2, O_3, and carbon dioxide is provided to ensure skin moisturizing, regeneration, anti-aging, and wound healing. CONSTITUTION: An external use skin composition contains 5-500 ug/ml of micro bubbles of oxygen(O_2), ozone(O_3), carbon dioxide(CO_2), or nitrogen monoxide(NO). The diameter of the micro bubbles is 0.01-2 um. The composition is used for skin moisturizing, regeneration, anti-aging, wound healing, slimming, or acne treatment. The composition is a cosmetic composition or pharmaceutical composition.

    Abstract translation: 目的:提供含有O_2,O_3和二氧化碳微泡的外用皮肤组合物,以确保皮肤保湿,再生,抗衰老和伤口愈合。 构成:外用皮肤组合物含有5-500ug / ml的氧气(O_2),臭氧(O_3),二氧化碳(CO_2)或一氧化氮(NO)的微气泡。 微气泡的直径为0.01-2μm。 该组合物用于皮肤保湿,再生,抗衰老,伤口愈合,减肥或痤疮治疗。 该组合物是化妆品组合物或药物组合物。

    2-사이클로펜텐-1-온 옥심 유도체를 유효성분으로 포함하는 지방대사질환 예방 및 치료용 약학 조성물
    35.
    发明公开
    2-사이클로펜텐-1-온 옥심 유도체를 유효성분으로 포함하는 지방대사질환 예방 및 치료용 약학 조성물 有权
    用于预防或治疗含有2-环戊烯-1-酮氧化衍生物的脂肪代谢相关疾病的药物组合物

    公开(公告)号:KR1020100103671A

    公开(公告)日:2010-09-27

    申请号:KR1020107017557

    申请日:2008-12-03

    CPC classification number: A61K31/15

    Abstract: PURPOSE: A pharmaceutical composition containing 2-cyclopentene-1-one oxime derivative is provided to promote adipose lysis in adipocytes(3T3-L1) and to prevent and treat lipid metabolic diseases including obesity and diabetes. CONSTITUTION: A pharmaceutical composition for preventing and treating lipid metabolic diseases contains 2-cyclopenten-1-one oxime derivative compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R1 is linear or branched C1-C10 alkyl group or C3-C7 cycloalkyl group, or phenyl group with or without substituent. The phenyl group is denoted by chemical formula 2. The pharmaceutical composition is used for preventing and treating obesity, diabetes, or dyslipidemia.

    Abstract translation: 目的:提供含有2-环戊烯-1-酮肟衍生物的药物组合物,以促进脂肪细胞(3T3-L1)中的脂肪裂解,并预防和治疗脂肪代谢疾病,包括肥胖和糖尿病。 构成:用于预防和治疗脂质代谢疾病的药物组合物含有化学式1的2-环戊烯-1-酮肟衍生物化合物或其药学上可接受的盐作为活性成分。 在化学式1中,R 1为直链或支链C 1 -C 10烷基或C 3 -C 7环烷基,或具有或不具有取代基的苯基。 苯基由化学式2表示。药物组合物用于预防和治疗肥胖症,糖尿病或血脂异常。

    바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
    36.
    发明公开
    바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 有权
    新型化合物,异构体或其药学上可接受的盐作为VANULLOID受体拮抗剂和含有其的药物组合物

    公开(公告)号:KR1020100053470A

    公开(公告)日:2010-05-20

    申请号:KR1020090108632

    申请日:2009-11-11

    Abstract: PURPOSE: A novel compound which functions as a vanilloid receptor 1(VR1) antagonist is provided to prevent or treat disease related to hair growth, rhinitis, and pancreatitis. CONSTITUTION: A vanilloid receptor antagonist compound is denoted by chemical formula I. A pharmaceutical composition contains the compound, isomer, or pharmaceutically acceptable salt thereof. The composition is used for preventing or treating arthritis disease, neuropathy, HIV related neuropathy, nerve injury, neurodegeneration, cerebral apoplexy, urinary incontinence, cough, neuropathy/allergy/inflammation skin disease, atopic dermatitis, psoriasis, pruritus, the prurigo, acouesthesia, aliasing, bregma anaphylaxis, effluvium, or alopecia.

    Abstract translation: 目的:提供作为香草素受体1(VR1)拮抗剂起作用的新型化合物,以预防或治疗与毛发生长,鼻炎和胰腺炎有关的疾病。 构成:香草素受体拮抗剂化合物由化学式I表示。药物组合物含有化合物,异构体或其药学上可接受的盐。 该组合物用于预防或治疗关节炎疾病,神经病,HIV相关神经病,神经损伤,神经变性,脑中风,尿失禁,咳嗽,神经病变/过敏/炎症皮肤病,特应性皮炎,牛皮癣,瘙痒,瘙痒症,麻醉, 混叠,原发性过敏性反应,流出或脱发。

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    37.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物,其异构体,或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号:KR1020080007329A

    公开(公告)日:2008-01-18

    申请号:KR1020077024002

    申请日:2006-03-15

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a pharmaceutical composition effective for preventing or treating pain, migraine, arthralgia, nerve injury, skin diseases, overactive bladder, irritable bowel syndrome, or the like. A compound as a vanilloid receptor antagonist, an isomer or a pharmaceutically acceptable salt thereof is represented by the following formula I. In formula I, X is NHCH2, CR11=CR12, NH, CHR11CHR12 or C=C, wherein each of R11 and R12 represents H, halogen, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl or phenyl; R1 is a C2-C5 alkenyl or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, or C2-C5 alkynyl; R2 is H, halogen, nitro, cyano, C1-C5 alkyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl(C1-C3)alkyl, wherein is each phenyl group is non-substituted or substituted with at least one substituent; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5 R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, hydroxy, C2-C5 alkenyloxy, C1-C5 alkoxy(C1-C5)alkoxy, C1-C5 alkoxy(C1-C5)alkoxy(C1-C5)alkyl, C1-C3 alkylpiperazinyl, piperazinyl(C1-C5)alkoxy, piperidinyl(C1-C5)alkoxy, C1-C5 alkoxy (C1-C5)alkylamino, C1-C7 alkylamino, morpholinyl, morpholinyl(C1-C5)alkyloxy, tetrahydropyranyloxy, phenyl or halogen, wherein each phenyl group is non-substituted or substituted with at least one substituent; each of R9 and R10 independently represents H, -SO2R13, -SOR13, C1-C5 alkyl, C1-C5 alkoxy, halo (C1-C5)alkyl, C2-C5 alkenyl, C1-C5 alkoxycarbonyl, C1-C5 alkylthio, phenyl or phenyl (C1-C3)alkyl, wherein each phenyl group is non-substituted or substituted with at least one substituent, and R13 is H, amino, C1-C5 alkyl, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, trifluoromethyl, phenyl or phenyl(C1-C3)alkyl.

    Abstract translation: 提供作为香草素受体拮抗剂的化合物以获得有效预防或治疗疼痛,偏头痛,关节痛,神经损伤,皮肤疾病,膀胱过度活动症,肠易激综合征等的药物组合物。 作为香草酸受体拮抗剂的化合物,其异构体或其药学上可接受的盐由下式I表示。在式I中,X为NHCH 2,CR 11 = CR 12,NH,CHR 11 CHR 12或C = C,其中R 11和R 12 表示H,卤素,C 1 -C 5烷基,C 1 -C 5烷氧基,卤代(C 1 -C 5)烷基或苯基; R1是C2-C5烯基或C2-C5炔基; R2是H,卤素,硝基,氰基,C1-C5烷基,C1-C5烷氧基,卤代(C1-C5)烷基,C2-C5烯基或C2-C5炔基; R2是H,卤素,硝基,氰基,C1-C5烷基,C1-C5烷氧基,卤代(C1-C5)烷基,C2-C5烯基,C2-C5炔基,羧基,C1-C5烷氧羰基,C1-C5烷硫基, 苯基或苯基(C1-C3)烷基,其中每个苯基是未取代的或被至少一个取代基取代; R3是H,C1-C5烷基,C1-C5烷氧基或卤代(C1-C5)烷基; R 4,R 5,R 6,R 7和R 8各自独立地表示H,羧基,C 1 -C 5烷基,硝基,C 2 -C 5烯基,C 1 -C 5烷氧基,C 2 -C 5炔基,卤代(C 1 -C 5)烷基,C 1 -C 5烷硫基 ,C1-C5烷基磺酰基,C1-C5烷基羰基,C1-C5烷氧基羰基,羟基,C2-C5链烯氧基,C1-C5烷氧基(C1-C5)烷氧基,C1-C5烷氧基(C1-C5)烷氧基(C1-C5)烷基 (C1-C5)烷氧基,C1-C5烷氧基(C1-C5)烷基氨基,C1-C7烷基氨基,吗啉基,吗啉基(C1-C5)烷氧基,四氢吡喃基氧基, 苯基或卤素,其中每个苯基未被取代或被至少一个取代基取代; R 9和R 10各自独立地表示H,-SO 2 R 13,-SOR 13,C 1 -C 5烷基,C 1 -C 5烷氧基,卤代(C 1 -C 5)烷基,C 2 -C 5烯基,C 1 -C 5烷氧基羰基,C 1 -C 5烷硫基,苯基或 苯基(C1-C3)烷基,其中每个苯基未被取代或被至少一个取代基取代,R 13是H,氨基,C 1 -C 5烷基,C 2 -C 5烯基,C 1 -C 5烷氧基,卤代(C1- C5)烷基,三氟甲基,苯基或苯基(C1-C3)烷基。

    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
    38.
    发明公开
    바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물 有权
    新化合物,其异构体,或其药学上可接受的盐作为VANILLOID受体拮抗剂; 和含有它们的药物组合物

    公开(公告)号:KR1020070114821A

    公开(公告)日:2007-12-04

    申请号:KR1020077024004

    申请日:2006-03-17

    Abstract: A compound as a vanilloid receptor antagonist is provided to obtain a high activity in preventing or treating pain, migraine, arthralgia, neuralgia, neural diseases, neural injury, skin diseases, irritable bowel syndrome, inflammatory diseases, cardiac diseases, etc. A compound as a vanilloid receptor antagonist is a compound represented by the following formula Ia or an isomer and/or pharmaceutically acceptable salt thereof. In formula Ia, X is CR11=CR12 or C=C, wherein each of R11 and R12 independently represents H, a halogen atom, C1-C5 alkyl or phenyl; each of R1 and R2 independently represents H, carboxyl, C1-C5 alkyl, halogen, nitro, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylcarbonylamino, C1-C5 alkylsulfonylamino, phenylsulfonylamino, C1-C5 alkylthio, C1-C5 alkylsulfonyl or C1-C5 alkoxycarbonyl; R3 is H, C1-C5 alkyl, C1-C5 alkoxy or halo(C1-C5)alkyl; each of R4, R5, R6, R7 and R8 independently represents H, carboxyl, C1-C5 alkyl, nitro, C2-C5 alkenyl, C1-C5 alkoxy, C2-C5 alkynyl, halo(C1-C5)alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, phenyl or halogen, wherein the phenyl is non-substituted or substituted with at least one substituent selected from carboxyl, C1-C5 alkyl, halogen, nitro, C2-C5 alkenyl, C1-C5 alkoxy, halo(C1-C5)alkyl, C1-C5 alkylcarbonyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl and C1-C5 alkoxycarbonyl; R9 is C1-C5 alkylsulfonyl or C2-C5 alkenylsulfonyl; and R10 is H, with the proviso that when R3 is not H, R11 and R13 cannot represent H at the same time.

    Abstract translation: 提供了一种作为香草素受体拮抗剂的化合物,用于预防或治疗疼痛,偏头痛,关节痛,神经痛,神经疾病,神经损伤,皮肤病,肠易激综合征,炎性疾病,心脏病等中的高活性。 香草酸受体拮抗剂是由下式Ia表示的化合物或其异构体和/或其药学上可接受的盐。 在式Ia中,X是CR 11 = CR 12或C = C,其中R 11和R 12各自独立地表示H,卤素原子,C 1 -C 5烷基或苯基; R1和R2各自独立地表示H,羧基,C1-C5烷基,卤素,硝基,C1-C5烷氧基,卤代(C1-C5)烷基,C1-C5烷基羰基,C1-C5烷基羰基氨基,C1-C5烷基磺酰基氨基,苯基磺酰基氨基, C1-C5烷硫基,C1-C5烷基磺酰基或C1-C5烷氧基羰基; R3是H,C1-C5烷基,C1-C5烷氧基或卤代(C1-C5)烷基; R4,R5,R6,R7和R8各自独立地表示H,羧基,C1-C5烷基,硝基,C2-C5烯基,C1-C5烷氧基,C2-C5炔基,卤代(C1-C5)烷基,C1-C5 烷基硫代,C 1 -C 5烷基磺酰基,C 1 -C 5烷基羰基,C 1 -C 5烷氧基羰基,苯基或卤素,其中苯基是未取代的或被至少一个选自羧基,C 1 -C 5烷基,卤素,硝基, C5链烯基,C1-C5烷氧基,卤代(C1-C5)烷基,C1-C5烷基羰基,C1-C5烷硫基,C1-C5烷基磺酰基和C1-C5烷氧基羰基; R9为C1-C5烷基磺酰基或C2-C5链烯基磺酰基; R 10为H,条件是当R3不为H时,R11和R13不能同时表示H。

    멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물
    39.
    发明授权
    멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물 有权
    黑色素形成抑制剂及含有其的化妆品组合物

    公开(公告)号:KR101823036B1

    公开(公告)日:2018-01-31

    申请号:KR1020127024172

    申请日:2011-03-30

    CPC classification number: A61K8/44 A61K8/675 A61Q19/00 A61Q19/02

    Abstract: 본발명은트라넥삼산(tranexamic acid) 및니코틴산아마이드를유효성분으로함유함으로써피부멜라닌세포의형성을억제하는멜라닌색소생성억제제및 상기멜라닌색소생성억제제를유효성분으로포함하는기미, 잡티, 주근깨, 피부톤, 피부결, 염증성과색소침착개선및 미백효과를갖는화장료조성물에관한것이다.

    Abstract translation: 本发明氨甲环酸(氨甲环酸)以及烟酰胺,由含有作为含有黑色素形成抑制剂和黑色素形成抑制剂以抑制皮肤黑素细胞的形成的活性成分的斑点,作为活性成分,污点,雀斑,和肤色 ,皮肤质地,炎症和色素沉着改善以及美白效果。

Patent Agency Ranking